Short-term effect on growth of two doses of GRF 1-44 in children with growth hormone deficiency: comparison with growth induced by methionyl-GH administration.
In a double-blind study 12 prepubertal children with idiopathic growth hormone (GH) deficiency were treated with growth hormone releasing factor (GRF) 1-44 in a dosage of 7.5 or 15 micrograms/kg body weight, administered once a day subcutaneously. With 7.5 micrograms/kg the average growth velocity increased from 2.5 to 4.6 cm/year, an insufficient response. With the higher dosage the average growth velocity increased from 2.7 to 7.0 cm/year, a similar increase as observed with GH therapy in subsequent periods. In 3 of the 6 children treated with the higher dose appropriate catch-up growth was observed. The growth response of the lower leg length was not always consistent with the statural growth response.
D001827:Body Height; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000172:deficiency* / Q000627:therapeutic use; D013007:Growth Hormone-Releasing Hormone / Q000627:therapeutic use*; D006728:Hormones / Q000627:therapeutic use*; D019382:Human Growth Hormone; D006801:Humans; D008297:Male
D006728:Hormones; D019382:Human Growth Hormone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone